Admittance Technologies, Inc., an Austin-based developer of a real-time blood volume measurement solution, has received a $1.99m investment from the Texas Emerging Technology Fund (ETF).
The company will use the proceeds to develop and commercialize its technology platform.
Marc Feldman, M.D., Founder and CEO, Admittance Technologies is conducting the proof of concept studies needed to commercialize CardioVol, a platform that provides a device that can determine the hemodynamic stability of ventricular tachycardia, the earliest detection of impending heart failure by measuring real-time blood volume using existing pacemaker components and lead systems.
Admittance is an Austin Technology Incubator company.
FinSMEs
19/01/2013